CIK 1910264
Long positions in SEC Section 13(f) securities (US-listed stocks, ADRs and ETFs), largest first · Δ vs 2025-Q4. A lagged quarterly snapshot (filed ≤45 days after quarter-end); excludes shorts, options, cash, and shares listed only on non-US exchanges — foreign companies held via a US listing or ADR (e.g. Alibaba, TSMC) ARE included.
As filed = each book applied at its quarter-end (what the reported book did) · As copyable = applied at its statutory 45-day filing deadline (what a 13F follower could have earned).
Computing…
Hypothetical modeled performance constructed with hindsight — not actual results, and not indicative of future results. See the Disclaimer.
| Industry group | Weight | Names |
|---|---|---|
| Pharmaceuticals & Biotechnology | 68.15% | 11 |
| Unclassified | 31.85% | 3 |
| # | Ticker | Name | Sector | Weight |
|---|---|---|---|---|
| 1 | ARCELLX INC | Unclassified | 29.43% | |
| 2 | MANE | Veradermics, Inc | Health Care | 16.57% |
| 3 | ZBIO | Zenas BioPharma, Inc. | Health Care | 10.76% |
| 4 | CRSP | CRISPR Therapeutics AG | Health Care | 10.59% |
| 5 | DSGN | Design Therapeutics, Inc. | Health Care | 7.59% |
| 6 | ORIC | Oric Pharmaceuticals, Inc. | Health Care | 6.39% |
| 7 | ALMS | ALUMIS INC. | Health Care | 4.72% |
| 8 | MLYS | Mineralys Therapeutics, Inc. | Health Care | 4.63% |
| 9 | SPRY | ARS Pharmaceuticals, Inc. | Health Care | 3.52% |
| 10 | ORKA | Oruka Therapeutics, Inc. | Health Care | 2.31% |
11/14 names classified · sector 68.1% of weight · industry 68.1% · mkt cap 68.1%; unclassified names shown, never dropped.
Sector is classified on each name's CURRENT fundamentals, not point-in-time — apparent sector drift can reflect the market re-rating a holding, not a manager trade. 13F is a lagged quarterly snapshot of long positions in US-listed securities only — foreign companies held via a US listing or ADR ARE included, but shares listed only on non-US exchanges (plus shorts, options and cash) are not. Latest quarter: 68.1% of the book is sector-classified (unclassified names shown, never dropped).
Only 0% of book weight classified — the grid is NOT representative of the whole book.
Classified: 0.0% of book weight (0/13 names) · unclassified 100.0%: , MANE, ZBIO, CRSP, DSGN, ORIC, ALMS, MLYS, SPRY, ORKA +3 more. Size: cap 70/20/10 bands; style: value/growth composite on our own metrics — not Morningstar's model.
No contribution data for this period.
| # | Security | Shares | Value | Weight | Δ QoQ |
|---|---|---|---|---|---|
| 1 | ARCELLX INC | 2,346,630 | $269M | 29.4% | HOLD |
| 2 | MANEVeradermics Inc | 2,401,868 | $152M | 16.6% | NEW |
| 3 | ZBIOZENAS BIOPHARMA INC | 5,037,854 | $98M | 10.8% | HOLD |
| 4 | CRSPCRISPR THERAPEUTICS AG | 2,038,763 | $97M | 10.6% | HOLD |
| 5 | DSGNDESIGN THERAPEUTICS INC | 6,526,476 | $69M | 7.6% | HOLD |
| 6 | ORICORIC PHARMACEUTICALS INC | 4,514,929 | $58M | 6.4% | HOLD |
| 7 | ALMSALUMIS INC | 1,959,896 | $43M | 4.7% | HOLD |
| 8 | MLYSMINERALYS THERAPEUTICS INC | 1,563,966 | $42M | 4.6% | HOLD |
| 9 | SPRYARS PHARMACEUTICALS INC | 4,012,903 | $32M | 3.5% | HOLD |
| 10 | ORKAORUKA THERAPEUTICS INC | 430,330 | $21M | 2.3% | HOLD |
| 11 | OCSOCULIS HOLDING AG | 641,022 | $17M | 1.9% | HOLD |
| 12 | NKTXNKARTA INC | 3,333,333 | $7M | 0.8% | HOLD |
| 13 | ENGENE HOLDINGS INC | 747,750 | $5M | 0.6% | HOLD |
| 14 | RAREULTRAGENYX PHARMACEUTICAL IN | 137,753 | $3M | 0.3% | HOLD |
| Security | 2024-Q4 | 2025-Q1 | 2025-Q2 | 2025-Q3 | 2025-Q4 | 2026-Q1 | Latest value |
|---|---|---|---|---|---|---|---|
| ARCELLX INC | 2.3M | 2.3M | 2.3M | 2.3M | 2.3M | 2.3M | $269M |
| MANEVeradermics Inc | — | — | — | — | — | 2.4M | $152M |
| ZBIOZENAS BIOPHARMA INC | 4.9M | 4.9M | 4.9M | 4.9M | 5.0M | 5.0M | $98M |
| CRSPCRISPR THERAPEUTICS AG | 1.0M | 1.0M | 1.0M | 2.0M | 2.0M | 2.0M | $97M |
| DSGNDESIGN THERAPEUTICS INC | 6.5M | 6.5M | 6.5M | 6.5M | 6.5M | 6.5M | $69M |
| ORICORIC PHARMACEUTICALS INC | — | — | 4.5M | 4.5M | 4.5M | 4.5M | $58M |
| ALMSALUMIS INC | 2.0M | 2.0M | 2.0M | 2.0M | 2.0M | 2.0M | $43M |
| MLYSMINERALYS THERAPEUTICS INC | 2.0M | 3.1M | 3.1M | 2.1M | 1.6M | 1.6M | $42M |
| SPRYARS PHARMACEUTICALS INC | 4.0M | 4.0M | 4.0M | 4.0M | 4.0M | 4.0M | $32M |
| ORKAORUKA THERAPEUTICS INC | 430K | 430K | 430K | 430K | 430K | 430K | $21M |
| OCSOCULIS HOLDING AG | — | 323K | 323K | 323K | 641K | 641K | $17M |
| NKTXNKARTA INC | 3.3M | 3.3M | 3.3M | 3.3M | 3.3M | 3.3M | $7M |
| ENGENE HOLDINGS INC | 748K | 748K | 748K | 748K | 748K | 748K | $5M |
| RAREULTRAGENYX PHARMACEUTICAL IN | — | — | — | — | 138K | 138K | $3M |
Shares reported each quarter by the largest current holdings. Green = added vs the prior filing of that name, red = trimmed, grey = roughly held; a dash is a quarter with no 13F on file (a gap is skipped, not read as an exit). 13F is filed up to 45 days after quarter-end. Up to 40 quarters (10 years) available — use the selector above.
Where this firm's principals came from and which firms its alumni went on to found.
